SNO 2022 - Society for Neuro-Oncology 27th Annual Scientific Meeting and Education Day
Nov 16 - Nov 20, 2022 | TampaFLUS
LARVOL is not affiliated with Society for Neuro-Oncology 27th Annual Scientific Meeting and Education Day and all trademarks, logos, and brand names are property of their respective owners
Showing 133 abstracts linked to Trials
CTIM-27 - Autologous tumor lysate-loaded dendritic cell vaccination improves survival in patients with newly diagnosed and recurrent glioblastoma: survival results from a phase 3 trial
NIMG-32 - Postprogression survival and MRI features at progression in MGMT-methylated glioblastoma following temozolomide (TMZ) or CCNU/TMZ therapy - an analysis of the CeTeG/NOA-09-trial
CTIM-12 - A phase I clinical trial on the intracranial administration of increasing doses of ipilimumab plus fixed dose nivolumab in patients with recurrent glioblastoma (rGB)
CTNI-12 - Phase II multicentric italian trial on repositioning of the antipsychotic drug chlorpromazine and its combination with temozolomide in MGMT unmethylated glioblastoma patients: the RACTAC trial
CTNI-42 - Genome-wide DNA methylation patterns in VERTU: A randomized phase II trial of veliparib, radiotherapy and temozolomide in patients with MGMT-unmethylated glioblastoma
INNV-21 - Feasibility of a virtual reality (VR) intervention targeting distress and anxiety in primary brain tumor (PBT) patients at the time of neuroimaging: Interim analysis of a phase 2 clinical trial
EXTH-12 - Preclinical and case study examination of the combination of the CLPP agonist ONC201 with the PI3K/AKT inhibitor paxalisib for the treatment of diffuse midline glioma.
NIMG-34 - Quantification of glycolytic flux reduction in recurrent glioblastoma after EGFR inhibition using molecular MR-PET
CTIM-28 - Multilamellar mRNA lipid particles induce immunologic reprogramming in canine and human glioblastoma patients
CTNI-18 - First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
CTNI-33 - CSNO2012001 study: A Phase III Trial on Adjuvant Temozolomide Chemotherapy with or without Interferon-alpha in Newly Diagnosed High-grade Gliomas
CTNI-60 - Preliminary results of binimetinib and encorafenib in adults with recurrent BRAF V600E-mutated high-grade glioma.
CTNI-61 - Clinical efficacy and predictive biomarkers of ONC201 in H3K27M-mutant diffuse midline glioma
CTNI-62 - Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion primary central nervous system (CNS) tumors
NIMG-21 - Interim analysis of a phase II study of multiparametric MR-guided high-dose response-adaptive radiotherapy with concurrent temozolomide in patients with newly diagnosed glioblastoma